記住我
N Engl J Med. 2019; 381: 1609-1620
. Treatment benefits were greater in patients with lower ejection fractions 2 Solomon SD Vaduganathan M L Claggett B et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure.Circulation. 2020; 141: 352-361
and post-hoc analyses identified greater benefit in those with recent HF hospitalization. 3 Vaduganathan M Claggett BL Desai AS et al. Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in hfpef.J Am Coll Cardiol. 2020; 75: 245-254
That patients with recent HF hospitalization might be an important target population among individuals with heart failure and mildly reduced or preserved ejection fraction is underscored by the potential benefit of sotagliflozin in this population the SOLOIST-WHF trial. 4 Bhatt DL Szarek M Steg PG et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.N Engl J Med. 2021; 384: 117-128
Recently, the FDA expanded the indication for sacubitril/valsartan to encompass potentially all patients with chronic HF, although the revised label stated that benefits are most clearly evident in those with an LVEF below normal. In light of these observations, we conducted more detailed analyses of the treatment effects in patients with recent hospitalization in PARAGON-HF, including those with LVEF above the normal range.
留言 (0)